Street View: Abbott's effective management could help it triumph over tariffs

Medical device maker Abbott Laboratories ABT.N maintained its annual profit forecast on Wednesday and said it expected U.S. tariffs to hit earnings by a "few hundred million dollars"

Median PT of 28 brokerages covering the stock is $145 - LSEG data

OPTIMISM FOR MEDTECH

J.P.Morgan ("overweight," PT: $135) says it is optimistic about co, citing strong fundamentals and effective management to mitigate tariff impacts

Piper Sandler ("overweight," PT: $145) says it is confident in co's diversified business model and its ability to navigate through periods of uncertainty while delivering sustainable growth

TD Cowen ("buy," PT: $145) sees co mitigating tariff impacts through strategic manufacturing adjustments and leveraging past successes

"We saw ABT rapidly respond to the COVID pandemic and build a multi billion-dollar Covid testing franchise in very little time. This precedent should give investors confidence that the plant optimization initiatives can succeed in a similar fashion" - TD

Jefferies ("hold," PT: $137) says co's ability to counteract tariff pressures is a positive surprise, following JNJ JNJ.N maintaining its guidance, which provides optimism for other medtech companies